drugset / Trial / NCT01015677
A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women. The primary study hypothesis is that one or more doses of MK-6913 will result in a significantly greater reduction from baseline, compared to placebo, in the number of moderate to very severe hot flashes after 4 weeks of treatment.
Timeline
- Start
- 2009-12-17
- Primary completion
- 2010-07-30
- Completion
- 2010-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Estradiol | Other / unclassified | 1 mg | — |
| Subject | MK-6913 | Small molecule | 25 mg | — |
| Subject | MK-6913 | Small molecule | 75 mg | — |
Indications
No indication recorded.